Emcure Pharmaceuticals Posts 63 Per Cent PAT Growth in Q4FY25

Emcure Pharmaceuticals

Pune: Emcure Pharmaceuticals Ltd. (NSE: EMCURE, BSE: 544210) has posted robust financial results for Q4FY25, reporting a 19.5% year-on-year increase in revenue to ₹2,116 crore and an impressive 63% YoY rise in profit after tax (PAT) to ₹197 crore. The results reflect strong momentum across both domestic and international markets.

Emcure Pharmaceuticals domestic business reported revenue of ₹929 crore, marking a 24.8% YoY increase, fueled by strong growth in the Women’s Health and Cardiology segments, along with emerging traction in Dermatology and OTC products.

The international business contributed ₹1,187 crore in revenue, growing 15.6% YoY, with standout 39.3% growth in emerging markets (EM).

The Canada business continued to perform steadily post the integration of Mantra, while Emcure also secured regulatory approvals and new product acquisitions in Europe, positioning the company for future expansion.

“Q4 was a solid quarter for Emcure Pharmaceuticals with broad-based growth across all segments,” said Satish Mehta, CEO and Managing Director. “Our strategy of investing in innovation, building a strong product pipeline, and expanding our international footprint is paying off. Going forward, we remain focused on enhancing margins through product launches and operational efficiencies.”

Operational Highlights – Q4FY25 vs Q4FY24:

  • Revenue from Operations: ₹2,116 Cr, up 19.5%
  • EBITDA: ₹390 Cr, up 25.2% (EBITDA margin: 18.4%)
  • Profit After Tax: ₹197 Cr, up 63.0%
  • Domestic Sales: ₹929 Cr, up 24.8%
  • International Sales: ₹1,187 Cr, up 15.6%
  • Emerging Markets: +39.3% YoY
  • Canada: +6.2% YoY
  • Europe: +1.7% YoY

The Board of Directors has recommended a final dividend of ₹3 per share for FY25.

Emcure Pharmaceuticals: R&D-driven Business Model

With an R&D-driven business model, Emcure Pharmaceuticals continues to expand its presence in 70+ countries, including major global markets like Europe and Canada. It ranks among India’s top 15 pharmaceutical companies by domestic sales as of June 2024.

Author

  • Salil Urunkar

    Salil Urunkar is a senior journalist and the editorial mind behind Sahyadri Startups. With years of experience covering Pune’s entrepreneurial rise, he’s passionate about telling the real stories of founders, disruptors, and game-changers.

Back to top